🇺🇸 Immune checkpoint inhibitor in United States
1 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 1
Most-reported reactions
- Thrombotic Microangiopathy — 1 report (100%)
Other Oncology approved in United States
Frequently asked questions
Is Immune checkpoint inhibitor approved in United States?
Immune checkpoint inhibitor does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Immune checkpoint inhibitor in United States?
John L. Villano, MD, PhD is the originator. The local marketing authorisation holder may differ — check the official source linked above.